礼来公司宣布,其药物Orforglipron在关键心血管风险因素方面,相较于基线水平,取得了具有临床意义的显著改善。
礼来公司宣布,其药物Orforglipron在关键心血管风险因素方面,相较于基线水平,取得了具有临床意义的显著改善。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.